ADCO-FLUPAIN

Country: South Africa

Language: English

Source: South African Health Products Regulatory Authority (SAHPRA)

Available from:

Adcock

Patient Information leaflet

INDICATIONS [/za_106.html#1]
  [/za_106.html#1]     [/za_106.html#1]
CONTRA-INDICATIONS [/za_106.html#1]
      [/za_106.html#1]
DOSAGE [/za_106.html#1]
      [/za_106.html#1]
SIDE-EFFECTS [/za_106.html#1]
  [/za_106.html#1]     [/za_106.html#1]
PREGNANCY [/za_106.html#1]
      [/za_106.html#1]
OVERDOSE [/za_106.html#1]

IDENTIFICATION [/za_106.html#1]
  [/za_106.html#1]    PATIENT INFORMATION
ADCO-FLUPAIN
SCHEDULING STATUS:
S2
PROPRIETARY NAME:
(and dosage form)
ADCO-FLUPAIN
SYRUP
COMPOSITION:
Each 5 mL contains:- 
TRIPROLIDINE
 Hydrochloride
        0,625 mg
PSEUDOEPHEDRINE
 Hydrochloride         15,0 mg
PARACETAMOL
        125,0 mg
Preserved with:-

Methyl Hydroxybenzoate
0,12% m/v
Propyl Hydroxybenzoate
0,02% m/v
Contains Alcohol
9,6% v/v
PHARMACOLOGICAL CLASSIFICATION:
A 5.8 Preparations for the Common Cold including Decongestants and Antihistaminics.
PHARMACOLOGICAL ACTION:
ADCO-FLUPAIN SYRUP has decongestive, antipyretic, antihistamine and analgesic properties.
INDICATIONS:
For the relief of symptoms such as nasal congestion, sniffing and headache associated with the common cold and
influenza.
CONTRA-INDICATIONS:
ADCO-FLUPAIN SYRUP should not be administered to patients suffering from cardiovascular disease (especially
coronary insufficiency), hypertension, thyrotoxicosis, prostatism, bladder dysfunction, narrow angle glaucoma and
pheochromocytoma. Individuals who have previously exhibited intolerance to 
ADCO-FLUPAIN SYRUP or any of its
constituents and in patients with a known hypersensitivity to any of the ingredients.
ADCO-FLUPAIN SYRUP is contra-indicated in patients being treated with monoamine oxidase inhibitors and within two
weeks of stopping such treatment as a hypertensive response may result.
Premature infants or neonates.
During an attack of asthma.
Avoid during cyclopropane, and h